Kolon TissueGene announced that the initial results of its US Phase 3 clinical trial for TG-C, a cellular gene therapy for osteoarthritis, have not yet met primary endpoints. The company, however, emphasizes this is not a failure, but rather a delay in commercialization. The trial's first interim analysis indicated a need for further evaluation and refinement of the treatment approach. Kolon TissueGene attributes the results to complexities in patient selection and variability in disease progression. They plan to continue the trial with revised protocols and patient criteria, anticipating eventual success. The company maintains confidence in TG-C’s potential and its long-term prospects in the substantial osteoarthritis treatment market. Further details of the trial will be disclosed at an upcoming investor conference.